Tandem Diabetes Care (TNDM) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 sales of $244.0 million (GAAP), up 31% year-over-year, driven by strong execution, product launches, and higher pump shipments in both U.S. and international markets.

• Returned to positive free cash flow and adjusted EBITDA, with notable increases in customers converting from multiple daily injections and robust cash reserves of $473.3 million.

• Gross margin improved to 51%, benefiting from pricing improvements and product mix, despite higher labor and overhead costs from scaling Tandem Mobi.

• Net loss for Q3 2024 was $23.3 million, or $(0.35) per share, narrowing from the prior year.

• Completed pivotal trial for Control-IQ in type 2 diabetes, with regulatory submission expected by year-end.

Financial highlights

• Q3 2024 worldwide sales: $244.0 million (up 31% year-over-year); U.S. sales: $171.7 million; international sales: $72.3 million.

• Gross margin: 51%; gross profit: $124.7 million.

• Adjusted EBITDA margin: 2% of sales; operating loss: $26.1 million; net loss: $23.3 million.

• Free cash flow: $22 million in Q3; cash and investments: $473.3 million at quarter end.

• Nearly 31,000 pumps shipped worldwide in Q3 2024, with U.S. shipments ~21,000 units and international shipments ~11,000 units.

Outlook and guidance

• Raised 2024 annual sales guidance to $903–$910 million, with U.S. sales at $645–$650 million and international sales at $258–$260 million.

• Reaffirmed full-year gross margin expectation of 51% and adjusted EBITDA breakeven.

• Seasonality expected to cause a step down in Q1 sales and profits, with margins building across 2025.

• Tandem Choice program impacts revenue timing, with deferred revenue to be recognized in Q4 2024.

• Management expects cash and investments plus future cash flows to fund ongoing business activities for at least the next 12 months.